{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T11:56:42Z","timestamp":1781611002427,"version":"3.54.5"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"City of Scientific Research and Technological Applications"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Biotechnol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Urinary bladder cancer remains a significant global health challenge, with effective early preventive strategies urgently needed to reduce incidence and progression. This study explores the prophylactic potential of artemisinin against N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN)-induced early-stage urothelial carcinoma in a mouse model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A multidisciplinary approach was used to evaluate artemisinin\u2019s molecular and physiological effects. Techniques included protein\u2013protein interaction (PPI) network analysis, molecular docking, gene expression profiling, histopathological evaluation, and systemic biomarker assessment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>PPI analysis revealed FGFR3, HRAS, and TP53 as central oncogenic drivers. Molecular docking confirmed strong binding affinities of artemisinin to these targets. Prophylactic artemisinin administration significantly downregulated FGFR3 and HRAS while upregulating TP53, indicating early correction of carcinogenic signaling. These molecular changes were associated with preserved bladder and renal histoarchitecture, normalized kidney function markers, and restored hematological profiles, reflecting systemic protection against BBN-induced toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Artemisinin effectively intercepts bladder carcinogenesis at multiple levels, modulating key genetic pathways and mitigating systemic damage. These findings provide compelling preclinical evidence supporting artemisinin as a promising prophylactic agent for bladder cancer prevention in high-risk populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12896-025-01039-4","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T08:27:21Z","timestamp":1758097641000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prophylactic role of artemisinin in modulating FGFR3, HRAS, and TP53 to prevent early-stage urothelial carcinoma in BBN-induced mouse models"],"prefix":"10.1186","volume":"25","author":[{"given":"Silvia","family":"Botrous","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayaat","family":"Elmaghraby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samar El","family":"Achy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehia","family":"Mustafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salah","family":"Abdel-Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,17]]},"reference":[{"key":"1039_CR1","doi-asserted-by":"publisher","unstructured":"W\u00e9ber Andr\u00e1s, Vignat J, Shah R, Morgan E, Laversanne M. P\u00e9ter Nagy, Istv\u00e1n Kenessey, and Ariana Znaor. Global burden of bladder cancer mortality in 2020 and 2040 according to GLOBOCAN estimates. World J Urol. 2024;42(1):237. https:\/\/doi.org\/10.1007\/s00345-024-04949-8.","DOI":"10.1007\/s00345-024-04949-8"},{"issue":"1","key":"1039_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/2090598X.2022.2152237","volume":"21","author":"H Awada","year":"2023","unstructured":"Awada H, Ali AH, Zeineddine MA. Hasan nassereldine, Zahy Abdul sater, and Deborah mukherji. The status of bladder cancer research worldwide, a bibliometric review and recommendations. Arab J Urol. 2023;21(1):1\u20139. https:\/\/doi.org\/10.1080\/2090598X.2022.2152237.","journal-title":"Arab J Urol"},{"key":"1039_CR3","doi-asserted-by":"publisher","unstructured":"Saginala K, Barsouk A, Aluru JS, Rawla P, Padala SA, Barsouk A. Epidemiology of bladder cancer. Med Sci (Basel). 2020;8(1):15. https:\/\/doi.org\/10.3390\/medsci8010015.","DOI":"10.3390\/medsci8010015"},{"key":"1039_CR4","doi-asserted-by":"publisher","unstructured":"Oliveira PA, C\u00e1rmen Vasconcelos-N\u00f3brega RM. Gil Da costa, and Regina Arantes-Rodrigues. The N-butyl-N-4-hydroxybutyl Nitrosamine mouse urinary bladder cancer model. Urothelial Carcinoma: Methods and Protocols. 2018. p. 155-67. https:\/\/doi.org\/10.1007\/978-1-4939-7234-0_13.","DOI":"10.1007\/978-1-4939-7234-0_13"},{"key":"1039_CR5","doi-asserted-by":"publisher","unstructured":"Korac-Prlic J, Degoricija M, Vilovi\u0107 K. Sandra vujevi\u0107, and Jano\u0161 terzi\u0107. BBN-driven urinary bladder cancer mouse model. Methods Cell Biol. 2021;163:77-92. https:\/\/doi.org\/10.1016\/bs.mcb.2020.10.020.","DOI":"10.1016\/bs.mcb.2020.10.020"},{"issue":"4","key":"1039_CR6","first-page":"727","volume":"26","author":"C Vasconcelos-N\u00f3brega","year":"2012","unstructured":"Vasconcelos-N\u00f3brega C, Colaco A, Lopes C, Oliveira PA. BBN as an urothelial carcinogen. Vivo. 2012;26(4):727\u201339. https:\/\/iv.iiarjournals.org\/content\/26\/4\/727\/tab-article-info.","journal-title":"Vivo"},{"key":"1039_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-019-02146-5","volume":"17","author":"M Degoricija","year":"2019","unstructured":"Degoricija M, Korac-Prlic J, Vilovic K, Ivanisevic T, Haupt B, Palada V, Petkovic M. Ivana karaman, and Janos terzic. The dynamics of the inflammatory response during BBN-induced bladder carcinogenesis in mice. J Translational Med. 2019;17:1\u201313. https:\/\/doi.org\/10.1186\/s12967-019-02146-5.","journal-title":"J Translational Med"},{"key":"1039_CR8","doi-asserted-by":"publisher","first-page":"102530","DOI":"10.1016\/j.ctrv.2023.102530","volume":"115","author":"C Ascione","year":"2023","unstructured":"Ascione C, Maria F, Napolitano D, Esposito A, Servetto S, Belli A, Santaniello S, Scagliarini F, Crocetto. Roberto bianco, and Luigi formisano. Role of FGFR3 in bladder cancer: treatment landscape and future challenges. Cancer Treat Rev. 2023;115:102530. https:\/\/doi.org\/10.1016\/j.ctrv.2023.102530.","journal-title":"Cancer Treat Rev"},{"key":"1039_CR9","doi-asserted-by":"crossref","unstructured":"Billerey C, Chopin D et al. Marie-H\u00e9l\u00e8ne Aubriot-Lorton, David Ricol, Sixtina Gil Diez de Medina, Bas Van Rhijn, Marie-Pierre Bralet Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol. 2001;158(6):1955-9.","DOI":"10.1016\/S0002-9440(10)64665-2"},{"issue":"6","key":"1039_CR10","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s00345-007-0213-4","volume":"25","author":"MA Knowles","year":"2007","unstructured":"Knowles MA. Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target. World J Urol. 2007;25(6):581\u201393. https:\/\/doi.org\/10.1007\/s00345-007-0213-4.","journal-title":"World J Urol"},{"issue":"12","key":"1039_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14744\/ejmo.2017.22931","volume":"7","author":"H Kodaz","year":"2017","unstructured":"Kodaz H, Kostek O, Hacioglu MB, Erdogan B, Kodaz CE, Hacibekiroglu I, Turkmen E. Sernaz uzunoglu, and Irfan cicin. Frequency of RAS mutations (KRAS, NRAS, HRAS) in human solid cancer. Breast Cancer. 2017;7(12):1\u20137. https:\/\/doi.org\/10.14744\/ejmo.2017.22931.","journal-title":"Breast Cancer"},{"key":"1039_CR12","doi-asserted-by":"publisher","unstructured":"Yee CH, Zheng Z, Shuman L, Yamashita H, Joshua I, Warrick X-R, Wu JD, Raman, David J. DeGraff. Maintenance of the bladder cancer precursor urothelial hyperplasia requires FOXA1 and persistent expression of oncogenic HRAS. Sci Rep. 2019;9(1):270. https:\/\/doi.org\/10.1038\/s41598-018-36720-6.","DOI":"10.1038\/s41598-018-36720-6"},{"issue":"6","key":"1039_CR13","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/ejhg.2013.251","volume":"22","author":"W Beukers","year":"2014","unstructured":"Beukers W, Hercegovac A, Ellen C. Zwarthoff. HRAS mutations in bladder cancer at an early age and the possible association with the Costello syndrome. Eur J Hum Genet. 2014;22(6):837\u20139. https:\/\/doi.org\/10.1038\/ejhg.2013.251.","journal-title":"Eur J Hum Genet"},{"issue":"11","key":"1039_CR14","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1054\/bjoc.2001.1823","volume":"84","author":"P Berggren","year":"2001","unstructured":"Berggren P, Steineck G, Adolfsson J, Hansson J, Jansson O, Larsson P, Sandstedt B, Wijkstr\u00f6m H, Hemminki K. p53 mutations in urinary bladder cancer. Br J Cancer. 2001;84(11):1505\u201311. https:\/\/doi.org\/10.1054\/bjoc.2001.1823.","journal-title":"Br J Cancer"},{"key":"1039_CR15","unstructured":"https:\/\/www.kegg.jp\/pathway\/hsa05219."},{"key":"1039_CR16","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s00240-003-0345-y","volume":"32","author":"SG Williams","year":"2004","unstructured":"Williams SG, Stein JP. Molecular pathways in bladder cancer. Urol Res. 2004;32:373\u201385. https:\/\/doi.org\/10.1007\/s00240-003-0345-y.","journal-title":"Urol Res"},{"issue":"9","key":"1039_CR17","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/nrc1697","volume":"5","author":"X-R Wu","year":"2005","unstructured":"Wu X-R. Urothelial tumorigenesis: a Tale of divergent pathways. Nat Rev Cancer. 2005;5(9):713\u201325. https:\/\/doi.org\/10.1038\/nrc1697.","journal-title":"Nat Rev Cancer"},{"key":"1039_CR18","doi-asserted-by":"publisher","unstructured":"Kaptein SJF, Thomas Efferth M, Leis S, Rechter S, Auerochs M, Kalmer CA, Bruggeman C, Vink T, Stamminger, Marschall M. The anti-malaria drug artesunate inhibits replication of cytomegalovirus in vitro and in vivo. Antiviral Res. 2006;69(2):60-9. https:\/\/doi.org\/10.1016\/j.antiviral.2005.10.003.","DOI":"10.1016\/j.antiviral.2005.10.003"},{"key":"1039_CR19","doi-asserted-by":"publisher","unstructured":"Hu Y, Guo N, Yang T, Wang JYW, Li X. The potential mechanisms by which artemisinin and its derivatives induce ferroptosis in the treatment of cancer. Oxid Med Cell Longev. 2022;2022:1458143. https:\/\/doi.org\/10.1155\/2022\/1458143.","DOI":"10.1155\/2022\/1458143"},{"key":"1039_CR20","doi-asserted-by":"publisher","unstructured":"Poupel F, Aghaei M, Movahedian A, Jafari SM, and Mohammad Keyvanloo Shahrestanaki. Dihydroartemisinin induces apoptosis in human bladder cancer cell lines through reactive oxygen species, mitochondrial membrane potential,cytochrome C pathway. Int J Prev Med. 2017;8(1):78. https:\/\/doi.org\/10.4103\/ijpvm.IJPVM_258_17.","DOI":"10.4103\/ijpvm.IJPVM_258_17"},{"key":"1039_CR21","doi-asserted-by":"crossref","unstructured":"Efferth T. From ancient herb to modern drug: Artemisia annua and Artemisinin for cancer therapy. Seminars in cancer biology. Volume 46. Academic; 2017. pp. 65\u201383.","DOI":"10.1016\/j.semcancer.2017.02.009"},{"issue":"2","key":"1039_CR22","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/ptr.5958","volume":"32","author":"A Zyad","year":"2018","unstructured":"Zyad A, Tilaoui M, Jaafari A. Moulay Ali oukerrou, and Hassan Ait mouse. More insights into the Pharmacological effects of Artemisinin. Phytother Res. 2018;32(2):216\u201329.","journal-title":"Phytother Res"},{"key":"1039_CR23","doi-asserted-by":"crossref","unstructured":"Ma Z, Woon CYN, Liu CG, Cheng JT, You M, Sethi G, Wong AL. Repurposing artemisinin and its derivatives as anticancer drugs: a chance or challenge? Front Pharmacol. 2021;12:828856.","DOI":"10.3389\/fphar.2021.828856"},{"issue":"1","key":"1039_CR24","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41392-024-01769-5","volume":"9","author":"Q Zhou","year":"2024","unstructured":"Zhou Q, Meng Y, Li D, Yao L, Le J, Liu Y, Sun Y, Zeng F. Xiang chen, and Guangtong deng. Ferroptosis in cancer: from molecular mechanisms to therapeutic strategies. Signal Transduct Target Therapy. 2024;9(1):55.","journal-title":"Signal Transduct Target Therapy"},{"issue":"5","key":"1039_CR25","first-page":"750","volume":"22","author":"X Yang","year":"2021","unstructured":"Yang X, Zheng Y, Liu L, Huang J, Wang F, Zhang J. Progress Study Anticancer Eff Artesunate Oncol Lett. 2021;22(5):750.","journal-title":"Progress Study Anticancer Eff Artesunate Oncol Lett"},{"key":"1039_CR26","doi-asserted-by":"crossref","unstructured":"Botrous S, Elmaghraby A, Achy SE, Mustafa Y, Abdel-Rahman S. Artemisinin pre-treatment fore cisplatin dosage enhances high grade urothelial carcinoma treatment in male albino mice via reverse gene expression modulation of FGFR3, HRAS, P53 and KDM6A. BMC Cancer. 2024;24(1):971.","DOI":"10.1186\/s12885-024-12683-y"},{"issue":"5","key":"1039_CR27","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.7150\/jca.36174","volume":"11","author":"T Wang","year":"2020","unstructured":"Wang T, Luo R, Li W, Xie HYS, Wang WXY, Chen B. Peide bai, and Jinchun xing. Dihydroartemisinin suppresses bladder cancer cell invasion and migration by regulating KDM3A and p21. J Cancer. 2020;11(5):1115. https:\/\/doi.org\/10.7150\/jca.36174.","journal-title":"J Cancer"},{"key":"1039_CR28","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s00280-017-3251-7","volume":"79","author":"A Bhaw-Luximon","year":"2017","unstructured":"Bhaw-Luximon A. Artemisinin and its derivatives in cancer therapy: status of progress, mechanism of action, and future perspectives. Cancer Chemother Pharmacol. 2017;79:451\u201366. https:\/\/doi.org\/10.1007\/s00280-017-3251-7.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1039_CR29","doi-asserted-by":"publisher","unstructured":"Huang Y, Yang Y, Guangqi Liu, and, Xu M. New clinical application prospects of artemisinin and its derivatives: a scoping review. Infect Dis Poverty. 2023;12(1):115. https:\/\/doi.org\/10.1186\/s40249-023-01152-6.","DOI":"10.1186\/s40249-023-01152-6"},{"key":"1039_CR30","unstructured":"OriGene Technologies. (n.d.). FGFR3 Mouse qPCR Primer Pair (NM_008010). Retrieved from https:\/\/www.origene.com\/catalog\/gene-expression\/qpcr-primer-pairs\/mp204828\/fgfr3-mouse-qpcr-primer-pair-nm_008010."},{"key":"1039_CR31","unstructured":"OriGene Technologies. (n.d.). H-RAS Mouse qPCR Primer Pair (NM_001130443). Retrieved from https:\/\/www.origene.com\/catalog\/gene-expression\/qpcr-primer-pairs\/mp220159\/H-RAS-mouse-qpcr-primer-pair-nm_001130443."},{"issue":"1","key":"1039_CR32","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1158\/1940-6207.CAPR-15-0199","volume":"9","author":"V Madka","year":"2016","unstructured":"Madka V, Mohammed A, Li Q, Zhang Y, Biddick L, Jagan MR, Patlolla S, Lightfoot, et al. Targeting mTOR and p53 signaling inhibits muscle invasive bladder cancer in vivo. Cancer Prev Res. 2016;9(1):53\u201362. https:\/\/doi.org\/10.1158\/1940-6207.CAPR-15-0199.","journal-title":"Cancer Prev Res"},{"key":"1039_CR33","doi-asserted-by":"publisher","unstructured":"Livak KJ, Thomas D, Schmittgen. Analysis of relative gene expression data using real-time quantitative PCR and the 2\u2009\u2013\u2009\u2206\u2206CT method. Methods. 2001;25(4):402-8. https:\/\/doi.org\/10.1006\/meth.2001.1262.","DOI":"10.1006\/meth.2001.1262"},{"key":"1039_CR34","unstructured":"Byrd DR, Robert K, Brookland MK, Washington JE, Gershenwald CC, Compton KR, Hess DC, Sullivan. and J. Milburn Jessup. AJCC cancer staging manual. Edited by Mahul B. Amin, Stephen B. Edge, and Frederick L. Greene. 8th ed. New York: Springer; 2017. p. 1024."},{"issue":"1","key":"1039_CR35","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s12672-024-01173-z","volume":"15","author":"DE Bogale","year":"2024","unstructured":"Bogale DE. The roles of FGFR3 and c-MYC in urothelial bladder cancer. Discover Oncol. 2024;15(1):295. https:\/\/doi.org\/10.1007\/s12672-024-01173-z.","journal-title":"Discover Oncol"},{"key":"1039_CR36","doi-asserted-by":"publisher","unstructured":"Marei HE, Althani A, Afifi N, Hasan A, Caceci T, Pozzoli G, Morrione A, Giordano A, Cenciarelli C. p53 signaling in cancer progression and therapy. Cancer Cell Int. 2021;21(1):703.. https:\/\/doi.org\/10.1186\/s12935-021-02396-8.","DOI":"10.1186\/s12935-021-02396-8"},{"issue":"4","key":"1039_CR37","first-page":"727","volume":"26","author":"C Vasconcelos-N\u00f3brega","year":"2012","unstructured":"Vasconcelos-N\u00f3brega C, Colaco A, Lopes C, Oliveira PA. BBN as an urothelial carcinogen. Vivo. 2012;26(4):727\u201339. https:\/\/iv.iiarjournals.org\/content\/26\/4\/727.short.","journal-title":"Vivo"},{"key":"1039_CR38","doi-asserted-by":"crossref","unstructured":"Faheem HMM, Sameh MM, El Nabtity. Tumor suppressive effect of artemisia annua extract in 7, 12-dimethylbenz [a] anthracene-induced breast cancer in Wistar rats. Thai J Pharm Sci 2020;44(4). http:\/\/www.tjps.pharm.chula.ac.th\/ojs\/index.php\/tjps\/article\/view\/187.","DOI":"10.56808\/3027-7922.2458"},{"key":"1039_CR39","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1007\/s13277-013-1193-1","volume":"35","author":"H-T Zhang","year":"2014","unstructured":"Zhang H-T, Wang Y-L, Zhang J, Qin-Xian Z. Artemisinin inhibits gastric cancer cell proliferation through upregulation of p53. Tumor Biology. 2014;35:1403\u20139. https:\/\/doi.org\/10.1007\/s13277-013-1193-1.","journal-title":"Tumor Biology"},{"key":"1039_CR40","doi-asserted-by":"publisher","unstructured":"Inamura K. Bladder cancer: new insights into its molecular pathology. Cancers (Basel). 2018;10(4):100. https:\/\/doi.org\/10.3390\/cancers10040100.","DOI":"10.3390\/cancers10040100"},{"key":"1039_CR41","doi-asserted-by":"publisher","unstructured":"Parada B, Reis Fl\u00e1vio, Cerejo R. Patr\u00edcia Garrido, Jos\u00e9 Sereno, Maria Xavier-Cunha, Paula Neto, Alfredo Mota, Arnaldo Figueiredo, and Frederico Teixeira. Omega-3 Fatty Acids Inhibit Tumor Growth in a Rat Model of Bladder Cancer. Biomed Res Int. 2013:368178. https:\/\/doi.org\/10.1155\/2013\/368178.","DOI":"10.1155\/2013\/368178"},{"issue":"8","key":"1039_CR42","doi-asserted-by":"publisher","first-page":"14298","DOI":"10.3390\/ijms150814298","volume":"15","author":"W Zuo","year":"2014","unstructured":"Zuo W, Wang Z-Z, Xue J. Artesunate induces apoptosis of bladder cancer cells by miR-16 regulation of COX-2 expression. Int J Mol Sci. 2014;15(8):14298\u2013312. https:\/\/doi.org\/10.3390\/ijms150814298.","journal-title":"Int J Mol Sci"},{"issue":"18","key":"1039_CR43","doi-asserted-by":"publisher","first-page":"8775","DOI":"10.1111\/jcmm.16833","volume":"25","author":"Xian-ying Lei","year":"2021","unstructured":"Lei Xian-ying, Tan Rui\u2010zhi, Jia J, Wu Song\u2010lin, Wen Cheng\u2010li, Lin X, Wang H, et al. Artesunate relieves acute kidney injury through inhibiting macrophagic Mincle\u2010mediated necroptosis and inflammation to tubular epithelial cell. J Cell Mol Med. 2021;25(18):8775\u201388. https:\/\/doi.org\/10.1111\/jcmm.16833.","journal-title":"J Cell Mol Med"},{"key":"1039_CR44","doi-asserted-by":"publisher","first-page":"1097206","DOI":"10.3389\/fphar.2023.1097206","volume":"14","author":"Q Jin","year":"2023","unstructured":"Jin Q, Liu T, Chen D, Yang L, Mao H, Ma F, Wang Y, Li P, Zhan Y. Therapeutic potential of Artemisinin and its derivatives in managing kidney diseases. Front Pharmacol. 2023;14:1097206. https:\/\/doi.org\/10.3389\/fphar.2023.1097206.","journal-title":"Front Pharmacol"},{"key":"1039_CR45","doi-asserted-by":"publisher","first-page":"5401760","DOI":"10.1155\/2022\/5401760","volume":"20221","author":"H Feng","year":"2022","unstructured":"Feng H, Wu T, Zhou Q, Li H, Liu T, Ma X, Yue R. Protective effect and possible mechanisms of Artemisinin and its derivatives for diabetic nephropathy: a systematic review and meta-analysis in animal models. Oxidative Med Cell Longev. 2022;20221:5401760. https:\/\/doi.org\/10.1155\/2022\/5401760.","journal-title":"Oxidative Med Cell Longev"},{"key":"1039_CR46","doi-asserted-by":"publisher","unstructured":"Tutun H, \u00d6zlem \u00d6zmen \u0130, Akta\u0219. Alper yal\u00e7\u0131n, and Ahmet t\u00fcrk. Investigation of the effects of artemisinin on testis and kidney injury induced by doxorubicin. (2019): 177\u201391. https:\/\/doi.org\/10.2478\/acve-2019-0014.","DOI":"10.2478\/acve-2019-0014"},{"key":"1039_CR47","doi-asserted-by":"publisher","unstructured":"Jalili C, Moradi D, Roshankhah S, Mohammad Reza S. Effect of pentoxifylline on kidney damage induced by nitrosamine in male rats. Res Pharm Sci. 2019;14(1):64-73. https:\/\/doi.org\/10.4103\/1735-5362.251854.","DOI":"10.4103\/1735-5362.251854"},{"key":"1039_CR48","doi-asserted-by":"publisher","unstructured":"Zhang H, Qi S, Song Y, Ling C. Artemisinin attenuates early renal damage on diabetic nephropathy rats through suppressing TGF-\u03b21 regulator and activating the Nrf2 signaling pathway. Life Sci. 2020;256:117966. https:\/\/doi.org\/10.1016\/j.lfs.2020.117966.","DOI":"10.1016\/j.lfs.2020.117966"},{"key":"1039_CR49","doi-asserted-by":"publisher","first-page":"1242432","DOI":"10.3389\/fonc.2023.1242432","volume":"13","author":"R Chatterjee","year":"2023","unstructured":"Chatterjee R, Shukla A, Chakrabarti K, Chatterji U. CLEC12A sensitizes differentially responsive breast cancer cells to the anti-cancer effects of Artemisinin by repressing autophagy and inflammation. Front Oncol. 2023;13:1242432. https:\/\/doi.org\/10.3389\/fonc.2023.1242432.","journal-title":"Front Oncol"},{"key":"1039_CR50","doi-asserted-by":"publisher","unstructured":"von Hagens C, Walter-Sack I, Goeckenjan M, Storch-Hagenlocher B, Sertel S, Els\u00e4sser M, Bjoern A, Remppis et al. Long-term add-on therapy (compassionate use) with oral artesunate in patients with metastatic breast cancer after participating in a phase I study (ARTIC M33\/2). Phytomedicine 2019;54:140\u20138. https:\/\/doi.org\/10.1016\/j.phymed.2018.09.178.","DOI":"10.1016\/j.phymed.2018.09.178"},{"issue":"2","key":"1039_CR51","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s00280-016-2960-7","volume":"77","author":"M K\u00f6nig","year":"2016","unstructured":"K\u00f6nig M, von Hagens C, Hoth S, Baumann I, Walter-Sack I, Edler L, Serkan Sertel. Investigation of ototoxicity of Artesunate as add-on therapy in patients with metastatic or locally advanced breast cancer: new audiological results from a prospective, open, uncontrolled, monocentric phase I study. Cancer Chemother Pharmacol. 2016;77(2):413\u201327. https:\/\/doi.org\/10.1007\/s00280-016-2960-7.","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["BMC Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12896-025-01039-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12896-025-01039-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12896-025-01039-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T11:42:41Z","timestamp":1781610161000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12896-025-01039-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,17]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1039"],"URL":"https:\/\/doi.org\/10.1186\/s12896-025-01039-4","relation":{},"ISSN":["1472-6750"],"issn-type":[{"value":"1472-6750","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,17]]},"assertion":[{"value":"11 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was performed in accordance with the guidelines for the care and use of laboratory animals approved by Institutional Animal Care and Use Committee AU-08-22-07-24-2-96 (Faculty of Medicine, Alexandria University, Egypt).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"All authors approved the final manuscript and the submission to the journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"102"}}